BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21798405)

  • 1. [Use of anti-VEGF (anti-vascular endothelial growth factor) in Retinopathy of Prematurity (ROP)].
    González Viejo I; Ferrer Novella C; Pueyo Royo V
    Arch Soc Esp Oftalmol; 2011 Jul; 86(7):207-8. PubMed ID: 21798405
    [No Abstract]   [Full Text] [Related]  

  • 2. Current and future trends in treatment of severe retinopathy of prematurity.
    Wallace DK; Wu KY
    Clin Perinatol; 2013 Jun; 40(2):297-310. PubMed ID: 23719311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab (avastin) for the treatment of retinopathy of prematurity.
    Beaulieu MJ
    Neonatal Netw; 2012; 31(4):242-7. PubMed ID: 22763251
    [No Abstract]   [Full Text] [Related]  

  • 4. [Retinopathy of prematurity - pathophysiologic mechanisms and new treatment options].
    Stahl A; Aisenbrey S; Krohne TU
    Klin Monbl Augenheilkd; 2012 Oct; 229(10):1024-9. PubMed ID: 22961043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [VEGF antibodies as therapy for retinopathy of prematurity].
    Oberacher-Velten IM; Helbig H
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
    Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
    JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
    Erol N; Gürsoy H; Sahin A; Basmak H
    J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.
    Hartnett ME
    Clin Perinatol; 2014 Dec; 41(4):925-43. PubMed ID: 25459781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
    Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
    Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
    Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
    Klufas MA; Chan RV
    J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity.
    Mititelu M; Chaudhary KM; Lieberman RM
    J Pediatr Ophthalmol Strabismus; 2012; 49(6):332-40. PubMed ID: 22938516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Nowroozzadeh MH
    Retina; 2009 Apr; 29(4):564-5; author reply 565-8. PubMed ID: 19262428
    [No Abstract]   [Full Text] [Related]  

  • 14. Temporal macular dimple in retinopathy of prematurity.
    Behera UC; Tripathy D; Singh J
    JAMA Ophthalmol; 2015 Apr; 133(4):e145348. PubMed ID: 25856652
    [No Abstract]   [Full Text] [Related]  

  • 15. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.
    Moran S; O'Keefe M; Hartnett C; Lanigan B; Murphy J; Donoghue V
    Acta Ophthalmol; 2014 Sep; 92(6):e496-7. PubMed ID: 24428792
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
    Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
    Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
    Eldweik L; Mantagos IS
    Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case report.
    Flavahan PW; Lavy TE; Wykes W
    Scott Med J; 2013 Aug; 58(3):130-2. PubMed ID: 23960050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New therapeutic approaches in the treatment of retinopathy of prematurity].
    Jandeck C
    Klin Monbl Augenheilkd; 2009 Nov; 226(11):914-20. PubMed ID: 19798624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Present-day conservative treatment retinopathy of prematurity.
    Monika M; Katarzyna KK; Leszek K
    Klin Oczna; 2013; 115(1):65-8. PubMed ID: 23882745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.